Topiramate-Induced Metabolic Acidosis Management

Diagnosis and Clinical Presentation

The American Gastroenterological Association notes that topiramate-induced metabolic acidosis is characterized by hyperchloremic non-anion gap metabolic acidosis, with bicarbonate levels below 22 mEq/L, and is often accompanied by neurological symptoms such as paresthesias, cognitive impairment, and speech difficulties, occurring in 28-51% of patients 1, 2, 3, 4, 5
The clinical presentation of topiramate-induced metabolic acidosis typically begins early in treatment, with a median onset of 14-17 days, and is caused by topiramate's inhibition of carbonic anhydrase, leading to renal bicarbonate loss and subsequent metabolic acidosis 1, 2

The American Gastroenterological Association recommends that topiramate be discontinued immediately with proper tapering to prevent seizures, and that patients with topiramate-induced metabolic acidosis receive aggressive oral or intravenous fluid hydration to prevent kidney stones and support renal function 1, 2, 6
The tapering protocol for topiramate discontinuation involves taking one capsule every other day for at least 1 week, then stopping completely, to minimize seizure risk while allowing metabolic recovery 1, 2, 5, 6
Alternative weight loss medication options, such as semaglutide 2.4 mg, liraglutide 3.0 mg, and naltrexone-bupropion ER, may be considered if continued pharmacotherapy is desired after topiramate discontinuation 10, 7, 5

The American Gastroenterological Association recommends repeat comprehensive metabolic panel to track bicarbonate levels and renal function, as well as urinalysis with pH, calcium, and citrate levels to assess for kidney stone risk 1, 2, 5
Blood pressure and heart rate monitoring are also recommended due to the phentermine component, which can cause cardiovascular effects 2, 7, 5